SOVREMENNAYA PEDIATRIYA.2015.5(69):29-35 
 

The concept of receptor occupancy to predict clinical efficacy: a comparison of second generation H1-antihistamines 
 

Sherwin Gillman, Michel Gillard, Margherita Strolin Benedetti 
CHOC PSF, St. Joseph Hospital, California, USA

UCB Pharma SA, Brussels, Belgium

UCB Pharma SA, Nanterre Cedex, France 
 

Second generation H1-antihistamines are considered first-line therapy for allergic rhinitis and chronic idiopathic urticaria, largely because of their nonsedating effects. Evaluating pharmacokinetic and pharmacodynamic parameters and clinical efficacyof a drug is important, but models to predict clinical efficacy are lacking. Receptor occupancy (RO), a predictor for human pharmacodynamics and antihistamine potency that takes into account the affinity of the drug for the receptor and its free plasma concentration, may be a more accurate way to predict a drug's clinical efficacy. This study was designed to assess the concept of RO as a surrogate for clinical efficacy, using examples of second generation oral antihistamines. A literature review was conducted using MEDLINE. Search terms included allergy, allergic rhinitis, drug efficacy, over-the-counter drugs, perennial allergic rhinitis, seasonal allergic rhinitis, second generation antihistamines, chronic idiopathic urticaria, and treatment outcomes. Abstracts and posters from recent allergy-related society meetings were also used. RO of several second generation H1-antihistamines was derived from noncomparative and head-to-head studies. Levocetirizine showed similar RO at 4 hours, both higher than that of desloratadine. Levocetirizine established higher RO than desloratadine at 12 and 24 hours. RO for these agents appeared to correlate with pharmacodynamic activity in skin wheal and flare studies and with efficacy in allergen challenge chamber studies. Parameters affecting RO included time from dosing, pH, and dosing regimen. RO did not appear to be linearly related to drug concentration. Results indicate that RO is an accurate predictor of in vivo pharmacodynamic activity and clinical efficacy.

Key words: Allergic rhinitis, antihistamine, chronic idiopathic urticaria, desloratadine, fexofenadine, histamine H1-antagonists, levocetirizine, receptor occupancy, treatment outcome. 
 

REFERENCES

1. Whomsley R, Benedetti MS. 2005. Development of new H1-antihistamines: The importance of pharmacokinetics in theevaluation of safe and therapeutically effective agents. Curr Med Chem. 4: 451. http://dx.doi.org/10.2174/156801405774330394

2. Plaut M, Valentine MD. 2005. Clinical practice. Allergic rhinitis. N Engl J Med. 353: 1934 —1944. http://dx.doi.org/10.1056/NEJMcp044141; PMid:16267324

3. Zuberbier T et al. 2006. EAACI/GA2LEN/EDF guideline: Management of urticaria. Allergy. 61: 321—331. http://dx.doi.org/10.1111/j.1398-9995.2005.00964.x; http://dx.doi.org/10.1111/j.1398-9995.2005.00962.x; PMid:16436141

4. Dykewicz MS et al. 1998. Diagnosis and management of rhinitis: Complete guidelines of the Joint Task Force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol. 81: 478 —518. http://dx.doi.org/10.1016/S1081-1206(10)63155-9; http://dx.doi.org/10.1016/S1081-1206(10)63152-3

5. Molimard M, Diquet B, Benedetti MS. 2004. Comparison of pharmacokinetics and metabolism of desloratadine, fexofenadine, levocetirizine and mizolastine in humans. Fundam Clin Pharmacol. 18: 399 —411. http://dx.doi.org/10.1111/j.1472-8206.2004.00254.x; PMid:15312146

6. Paton DM, Webster DR. 1985. Clinical pharmacokinetics of H1-receptor antagonists (the-antihistamines). Clin Pharmacokinet. 10: 477— 497. http://dx.doi.org/10.2165/00003088-198510060-00002; PMid:2866055

7. Scheife RT, Cramer WR. 1996. Sedative and cardiovascular profile of newer-antihistamines. Consult Pharm. 11: 1037—1053.

8. Markham A, Wagstaff AJ. 1998. Fexofenadine. Drugs. 55: 269 —274. http://dx.doi.org/10.2165/00003495-199855020-00012; PMid:9506246

9. Waldman SA. 2002. Does potency predict clinical efficacy? Illustration through an-antihistamine model. Ann Allergy Asthma Immunol. 89: 7—11. http://dx.doi.org/10.1016/S1081-1206(10)61904-7

10. Bourne HR, von Zastrow M. 2007. Drug receptors and pharmacodynamics. In Basic and Clinical Pharmacology, 10^th ed. Katzung BG (Ed). New York, McGraw-Hill Medical: 11—33. PMid:17536929

11. Holford NHG. 2007. Pharmacokinetics and pharmacodynamics: Rational dosing and the time course of drug action. In Basic and Clinical Pharmacology, 10^th ed. Katzung BG (Ed). New York, McGraw-Hill Medical: 34 — 49.

12. Gillard M et al. 2005. Histamine H1-receptor occupancy and pharmacodynamics of second generation H1-antihistamines. Inflamm Res. 54: 367—369. http://dx.doi.org/10.1007/s00011-005-1368-3; PMid:16273334

13. Weiland GA, Molinoff PB. 1981. Quantitative analysis of drugreceptor interactions. I. Determination of kinetic and equilibrium properties. Life Sci. 29: 313—330. http://dx.doi.org/10.1016/0024-3205(81)90324-6

14. Strolin Benedetti M et al. 2006. Estimation of receptor occupancy. When is this relevant for the efficacy of an H1-antihistamine? Allergy Clin Immunol Int. 18: 131—133.

15. Strolin Benedetti M et al. 2007. Pharmacodynamics of latest generation H1-antihistamines: Relevance of drug concentrations at receptor sites and of affinity values for H1-receptors. Allergy Clin Immunol Int J World Allergy Org. Suppl 2: 162—166.

16. Gillard M et al. 2002. Binding characteristics of cetirizine and levocetirizine to human H1-histamine receptors: Contribution of Lys(191) and Thr(194). Mol Pharmacol. 61: 391—399. http://dx.doi.org/10.1124/mol.61.2.391; PMid:11809864

17. Jokuti A et al. 2004. Histamine metabolism is altered in nasal polyposis. Inflamm Res. 53; suppl 1: S93—S94. http://dx.doi.org/10.1007/s00011-003-0345-y; PMid:15054636

18. Petersen LJ et al. 1997. Histamine is released in the wheal but not the flare following challenge of human skin in vivo: A microdialysis study. Clin Exp Allergy. 27: 284 — 295. http://dx.doi.org/10.1111/j.1365-2222.1997.tb00707.x; PMid:9088655

19. Halmerbauer G et al. 1999. In vivo histamine release during the first minutes after deliberate sting challenges correlates with the severity of allergic symptoms. Pediatr Allergy Immunol. 10: 53—57. http://dx.doi.org/10.1034/j.1399-3038.1999.101012.x; PMid:10410918

20. Venza I et al. 2004. Quantitative determination of histamine in tears during conjunctivitis by a novel HPLC method. Ophthalmic Res. 36: 62— 69. http://dx.doi.org/10.1159/000076112; PMid:15007242

21. Pawankar R. 2005. Mast cells in allergic airway disease and chronic Rhinosinusitis. Chem Immunol Allergy. 87: 111—129. http://dx.doi.org/10.1159/000087639; PMid:16107767

22. Simons K et al. 2008. Hydroxyzine and its active metabolite cetirizine: H1-receptor occupancy in healthy elderly adults. Allergy. 63; suppl 88: 541. Abs 1495.

23. Tashiro M et al. 2004. Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography. J Clin Pharmacol. 44: 890 —900. http://dx.doi.org/10.1177/0091270004267590; PMid:15286093

24. Tashiro M et al. 2005. Brain histamine H1-receptor occupancy of orally administered-antihistamines measured by positron emission tomography with (11)C-doxepin in a placebo-controlled crossover study design in healthy subjects: A comparison of olopatadine and ketotifen. Br J Clin Pharmacol. 61: 16 —26. http://dx.doi.org/10.1111/j.1365-2125.2005.02514.x; PMid:16390347 PMCid:PMC1884984

25. Strolin Benedetti M et al. 2006, 10-14 June. Histamine H1-receptor occupancy following single and repeated administration of H1-antihistamines. Presented at the 25^th Congress of the European Academy of Allergology and Clinical Immunology. Vienna, Austria. Abs 1454.

26. Strolin Benedetti M et al. 2007, 9-13 June. Histamine H1-receptor occupancy by levoceterizine and fexofenadine in allergic rhinitis and chronic idiopathic urticaria. Presented at the 26^th EEACI Congress. Goteborg, Sweden. Abs 76247. PMCid:PMC2253696

27. Frossard N et al. 2008. Inhibition of allergen-induced wheal and flare reactions by levocetirizine and desloratadine. Br J Clin Pharmacol. 65: 172—179. http://dx.doi.org/10.1111/j.1365-2125.2007.03009.x; PMid:17953719 PMCid:PMC2253696

28. Strolin Benedetti M et al. 2007. Evaluation of the receptor occupancy by desloratadine and levocetirizine in allergic subjects. World Allergy Org J. Abs. 514: S163—S164. http://dx.doi.org/10.1097/01.WOX.0000301783.19727.31

29. Meltzer EO, Gillman SA. 2007. Efficacy of fexofenadine versus desloratadine in suppressing histamine-induced wheal and flare. Allergy Asthma Proc. 28: 67—73. http://dx.doi.org/10.2500/aap.2007.28.2895; http://dx.doi.org/10.1089/pai.2007.0015; PMid:17390761

30. Vermeulen ME et al. 2004. The impact of extracellular acidosis on dendritic cell function. Crit Rev Immunol. 24: 363—384. http://dx.doi.org/10.1615/CritRevImmunol.v24.i5.40; PMid:15663364

31. Gillard M, Chatelain P. 2006. Changes in pH differently affect the binding properties of histamine H1 receptor antagonists. Eur J Pharmacol. 20: 205—514. http://dx.doi.org/10.1016/j.ejphar.2005.11.051; PMid:16388798

32. Strolin Benedetti M et al. 2007, 9-13 June. The degree of receptor occupancy in the interpretation of the pharmacodynamics of levocetirizine. Presented at the XXVIth Congress of the European Academy of Allergology and Clinical Immunology. Goteborg, Sweden. PMCid:PMC2253696

33. Tighe KE et al. 1999. Persistently high plasma morphine-6-glucuronide levels despite decreased hourly patient-controlled analgesia morphine use after single-dose diclofenac: Potential for opioid-related toxicity. Anesth Analg. 88: 1137—1142. http://dx.doi.org/10.1213/00000539-199905000-00032; http://dx.doi.org/10.1097/00000539-199905000-00032; PMid:10320184

34. Strolin Benedetti M et al. 2007, 2–6 Dec. Relationship between histamine H1 receptor occupancy (RO) and reduction of symptoms of seasonal allergic rhinitis (SAR) by levocetirizine (L) in subjects exposed to pollen in an environmental exposure unit (EEU). Presented at the 20^th World Allergy Congress. Bangkok, Thailand. Poster 252. http://dx.doi.org/10.1097/01.wox.0000301353.56676.7e

35. Simons KJ et al. 2006, 3-7 March. Levocetirizine: H1-receptor occupancy in allergic children age 6–11 years. Poster Presented at the 62^nd Annual American Academy of Allergy, Asthma and Immunology Meeting. Miami Beach, FL.

36. Le Lamer S, Strolin Benedetti M. 2007. Pharmacokinetics of levocetirizine in children of 1-2 years and rationale for dosing regimen. Allergy. 62; Suppl 83: 306—307.

37. Cranswick N et al. 2005. Levocetirizine in 1-2 year old children: Pharmacokinetic and pharmacodynamic profile. Int J Clin Pharmacol Ther. 43: 172—177. http://dx.doi.org/10.5414/CPP43172; PMid:15966463

38. Bousquet J et al. 2008. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy. 63; suppl 86; 8: 160.

39. Powell RJ et al. 2007. BSACI guidelines for the management of chronic urticaria and angiooedema. Clin Exp Allergy. 37: 631—650. http://dx.doi.org/10.1111/j.1365-2222.2007.02678.x; PMid:17456211